(CLVT) CLARIVATE - Ratings and Ratios
Patent, Trademark, Database, Research, Drug
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 54.4% |
| Value at Risk 5%th | 75.5% |
| Relative Tail Risk | -15.58% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.75 |
| Alpha | -55.65 |
| CAGR/Max DD | -0.35 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.588 |
| Beta | 1.400 |
| Beta Downside | 1.344 |
| Drawdowns 3y | |
|---|---|
| Max DD | 73.46% |
| Mean DD | 43.45% |
| Median DD | 43.45% |
Description: CLVT CLARIVATE November 09, 2025
Clarivate Plc (NYSE: CLVT) is a global information-services firm that delivers research-and-analytics solutions across three segments: Academia & Government, Life Sciences & Healthcare, and Intellectual Property. Its portfolio includes ProQuest One (multidisciplinary content libraries), Alma/Polaris/Vega (integrated library-management platforms), IPFolio/FoundationIP (IP-portfolio management), Derwent Innovation (patent search), CompuMark (trademark services), and Cortellis (drug-development intelligence).
In FY 2023 the company generated approximately $1.6 billion in revenue, with subscription-based services accounting for roughly 70 % of that total and delivering an operating margin near 30 %. Growth was driven primarily by continued expansion in the life-sciences intelligence suite (Cortellis) and the integration of the ProQuest acquisition, which added a sizable university-library customer base.
Key macro drivers for Clarivate include sustained corporate R&D spending (global R&D outlays grew ~5 % YoY in 2023), rising university research funding, and increasing demand for IP analytics as firms seek to protect and monetize patents in high-tech sectors. The shift toward AI-enhanced literature discovery and data-analytics platforms further underpins the company’s long-term growth narrative.
For a deeper, data-driven valuation of CLVT, you may find the analytics on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (-396.0m TTM) > 0 and > 6% of Revenue (6% = 150.1m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -0.55pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -7.94% (prev -7.24%; Δ -0.70pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 609.9m > Net Income -396.0m (YES >=105%, WARN >=100%) |
| Net Debt (4.16b) to EBITDA (721.9m) ratio: 5.76 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (668.3m) change vs 12m ago -7.01% (target <= -2.0% for YES) |
| Gross Margin 65.76% (prev 59.11%; Δ 6.65pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 21.51% (prev 21.42%; Δ 0.08pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.12 (EBITDA TTM 721.9m / Interest Expense TTM 269.3m) >= 6 (WARN >= 3) |
Altman Z'' -1.50
| (A) -0.02 = (Total Current Assets 1.29b - Total Current Liabilities 1.49b) / Total Assets 11.23b |
| (B) -0.67 = Retained Earnings (Balance) -7.52b / Total Assets 11.23b |
| (C) -0.00 = EBIT TTM -32.2m / Avg Total Assets 11.63b |
| (D) 0.78 = Book Value of Equity 4.90b / Total Liabilities 6.32b |
| Total Rating: -1.50 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 42.21
| 1. Piotroski 3.50pt |
| 2. FCF Yield 5.02% |
| 3. FCF Margin 13.40% |
| 4. Debt/Equity 0.91 |
| 5. Debt/Ebitda 5.76 |
| 6. ROIC - WACC (= -5.55)% |
| 7. RoE -7.89% |
| 8. Rev. Trend -12.45% |
| 9. EPS Trend -51.31% |
What is the price of CLVT shares?
Over the past week, the price has changed by -5.25%, over one month by -1.15%, over three months by -20.05% and over the past year by -35.16%.
Is CLVT a buy, sell or hold?
- Strong Buy: 3
- Buy: 2
- Hold: 4
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the CLVT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.9 | 43.7% |
| Analysts Target Price | 4.9 | 43.7% |
| ValueRay Target Price | 2.6 | -24.8% |
CLVT Fundamental Data Overview December 05, 2025
P/E Forward = 5.5772
P/S = 1.0078
P/B = 0.4964
P/EG = 0.1712
Beta = 1.534
Revenue TTM = 2.50b USD
EBIT TTM = -32.2m USD
EBITDA TTM = 721.9m USD
Long Term Debt = 4.42b USD (from longTermDebt, last quarter)
Short Term Debt = 37.4m USD (from shortTermDebt, last quarter)
Debt = 4.48b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.16b USD (from netDebt column, last quarter)
Enterprise Value = 6.68b USD (2.52b + Debt 4.48b - CCE 318.7m)
Interest Coverage Ratio = -0.12 (Ebit TTM -32.2m / Interest Expense TTM 269.3m)
FCF Yield = 5.02% (FCF TTM 335.2m / Enterprise Value 6.68b)
FCF Margin = 13.40% (FCF TTM 335.2m / Revenue TTM 2.50b)
Net Margin = -15.83% (Net Income TTM -396.0m / Revenue TTM 2.50b)
Gross Margin = 65.76% ((Revenue TTM 2.50b - Cost of Revenue TTM 856.5m) / Revenue TTM)
Gross Margin QoQ = 64.98% (prev 67.24%)
Tobins Q-Ratio = 0.60 (Enterprise Value 6.68b / Total Assets 11.23b)
Interest Expense / Debt = 1.53% (Interest Expense 68.5m / Debt 4.48b)
Taxrate = -15.51% (negative due to tax credits) (3.80m / -24.5m)
NOPAT = -37.2m (EBIT -32.2m * (1 - -15.51%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 0.87 (Total Current Assets 1.29b / Total Current Liabilities 1.49b)
Debt / Equity = 0.91 (Debt 4.48b / totalStockholderEquity, last quarter 4.90b)
Debt / EBITDA = 5.76 (Net Debt 4.16b / EBITDA 721.9m)
Debt / FCF = 12.41 (Net Debt 4.16b / FCF TTM 335.2m)
Total Stockholder Equity = 5.02b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.53% (Net Income -396.0m / Total Assets 11.23b)
RoE = -7.89% (Net Income TTM -396.0m / Total Stockholder Equity 5.02b)
RoCE = -0.34% (EBIT -32.2m / Capital Employed (Equity 5.02b + L.T.Debt 4.42b))
RoIC = -0.39% (negative operating profit) (NOPAT -37.2m / Invested Capital 9.51b)
WACC = 5.16% (E(2.52b)/V(7.00b) * Re(11.18%) + D(4.48b)/V(7.00b) * Rd(1.53%) * (1-Tc(-0.16)))
Discount Rate = 11.18% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.25%
[DCF Debug] Terminal Value 66.46% ; FCFE base≈371.3m ; Y1≈349.5m ; Y5≈328.6m
Fair Price DCF = 5.54 (DCF Value 3.66b / Shares Outstanding 661.4m; 5y FCF grow -7.54% → 3.0% )
EPS Correlation: -51.31 | EPS CAGR: -6.33% | SUE: 0.19 | # QB: 0
Revenue Correlation: -12.45 | Revenue CAGR: 2.85% | SUE: 3.31 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.14 | Chg30d=-0.000 | Revisions Net=-4 | Analysts=9
EPS next Year (2026-12-31): EPS=0.67 | Chg30d=-0.001 | Revisions Net=-1 | Growth EPS=+2.0% | Growth Revenue=-2.1%
Additional Sources for CLVT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle